Insights
Search Results
Client Highlights
9.12.25
Wilson Sonsini Advises Avidity Biosciences on Patent Matters Related to $600 Million Upsized Public Offering
On September 12, 2025, Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), announced the pricing of its upsized underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $40.00 per share. All of the shares to be sold in the offering are to be sold by Avidity. The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $600 million. Wilson Sonsini Goodrich & Rosati is advising Avidity Biosciences on patent matters related to the transaction.
Client Highlights
5.20.25
Firm Advises Sirius on Patent Matters Related to CRISPR Therapeutics Collaboration
On May 20, 2025, CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Sirius Therapeutics, a clinical-stage biotech company developing innovative small interfering RNA (siRNA) therapies for global markets, announced a strategic partnership to develop and commercialize novel siRNA therapies. Wilson Sonsini Goodrich & Rosati advised Sirius on patent matters related to the transaction.
Under the terms of the agreement, CRISPR Therapeutics will make an upfront payment of $25 million in cash and $70 million in equity to Sirius. The companies will jointly develop SRSD107—a next-generation, long-acting Factor XI (FXI) siRNA for the treatment of thromboembolic disorders—under a 50-50 cost and profit-sharing structure. CRISPR Therapeutics will lead commercialization in the U.S., while Sirius will be responsible for commercialization in Greater China. Additionally, CRISPR Therapeutics will have the option to nominate up to two siRNA targets for research and development. For each target, CRISPR Therapeutics will fund research and retain opt-in rights to lead clinical development and commercialization. Sirius will be eligible to receive milestone payments, as well as tiered royalties ranging from high-single to low-double digits.
The Wilson Sonsini team that advised Sirius on patent matters related to the transaction was led by Minyoung Shin and included Mike Hostetler, Hee Min Noh, Jen Zeng, and Tiara Wong.
For more information, please see the companies’ news release. Additional coverage is available in Fierce Biotech and BioSpace.
Under the terms of the agreement, CRISPR Therapeutics will make an upfront payment of $25 million in cash and $70 million in equity to Sirius. The companies will jointly develop SRSD107—a next-generation, long-acting Factor XI (FXI) siRNA for the treatment of thromboembolic disorders—under a 50-50 cost and profit-sharing structure. CRISPR Therapeutics will lead commercialization in the U.S., while Sirius will be responsible for commercialization in Greater China. Additionally, CRISPR Therapeutics will have the option to nominate up to two siRNA targets for research and development. For each target, CRISPR Therapeutics will fund research and retain opt-in rights to lead clinical development and commercialization. Sirius will be eligible to receive milestone payments, as well as tiered royalties ranging from high-single to low-double digits.
The Wilson Sonsini team that advised Sirius on patent matters related to the transaction was led by Minyoung Shin and included Mike Hostetler, Hee Min Noh, Jen Zeng, and Tiara Wong.
For more information, please see the companies’ news release. Additional coverage is available in Fierce Biotech and BioSpace.
Client Highlights
5.12.25
Firm Advises HAYA Therapeutics on Patent Matters Related to $65 Million Series A Financing
On May 8, 2025, HAYA Therapeutics, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases, announced that the company has raised $65 million in Series A funding. The round was led by Sofinnova Partners and Earlybird Venture Capital, with participation from Eli Lilly, ATHOS, +ND Capital, Alexandria Venture Investments, and LifeLink Ventures, with additional support from existing investors. Wilson Sonsini Goodrich & Rosati advised HAYA Therapeutics on patent matters related to the transaction.
Client Highlights
5.12.25
Firm Advises Sirius Therapeutics on Patent Matters Related to $50 Million Series B2 Financing
On May 9, 2025, biotechnology company Sirius Therapeutics announced that it has successfully completed nearly $50 million Series B2 financing. A corporate venture capital firm led the financing round and was joined by new investor BioTrack Capital and existing investors OrbiMed, Creacion Ventures, and Hankang Capital. Wilson Sonsini Goodrich & Rosati advised Sirius Therapeutics on patent matters related to the transaction.
Client Highlights
9.05.24
Wilson Sonsini Advises HAYA Therapeutics on Patent Matters Related to Collaboration with Eli Lilly
On September 4, 2024, HAYA Therapeutics, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, announced a multi-year agreement with Eli Lilly and Company to apply HAYA’s advanced RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. Wilson Sonsini Goodrich & Rosati advised HAYA on patent matters related to the transaction.
Client Highlights
8.19.24
Firm Advises Avidity Biosciences on IP Matters Related to Public Offering
On August 19, 2024, Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), announced that it has closed its previously announced underwritten public offering of 8,418,000 shares of its common stock, including 1,098,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $41.00 per share. The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $345.1 million. Wilson Sonsini Goodrich & Rosati is patent counsel to Avidity and represented the company in IP matters related to this transaction.
Client Highlights
6.18.24
Wilson Sonsini Advises Avidity Biosciences on Patent Matters Related to $461 Million Public Offering
On June 17, 2024, Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), announced that it had closed an underwritten public offering of 12,132,500 shares of its common stock, including 1,582,500 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $38.00 per share. The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $461.0 million. Wilson Sonsini Goodrich & Rosati advised Avidity on patent matters related to the transaction.
Client Highlights
2.29.24
Firm Advises Avidity Biosciences on Patent Matters Related to $400 Million Private Placement
On February 29, 2024, Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), announced that it has agreed to sell 15,224,773 shares of its common stock at a price of $16.50 per share and pre-funded warrants to purchase 9,030,851 shares of its common stock at a price per pre-funded warrant of $16.4990 to a select group of institutional and accredited healthcare specialist investors in an oversubscribed private placement. Wilson Sonsini Goodrich & Rosati advised Avidity on patent matters related to the transaction.